Nasdaq Mxct News Today

Valmark Advisers Inc. bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 83,927 shares of the company’s stock, valued at approximately $394,000. Valmark Advisers Inc. owned about 0.08% of MaxCyte […]

Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs...

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...

MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares in the company, […]

MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $4.59, but opened at $4.98. MaxCyte shares last traded at $5.14, with a volume of 235,852 shares changing hands. Wall Street Analyst Weigh In Several research firms have recently issued reports on MXCT. Stephens […]

MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – William Blair lifted their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.41) for the year, up from their prior forecast of ($0.45). William […]

MaxCyte (NASDAQ:MXCT – Get Free Report) and FOXO Technologies (NYSE:FOXO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk. Risk and Volatility MaxCyte has a beta of […]

Royce & Associates LP grew its stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) by 14.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 307,925 shares of the company’s stock after purchasing an additional 37,800 shares during the period. Royce & Associates […]

MaxCyte (NASDAQ:MXCT – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, August 9th. Analysts expect MaxCyte to post earnings of ($0.09) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link. MaxCyte (NASDAQ:MXCT – Get Free […]